Antifungal resistance of ocular isolates from fungal keratitis patients in South India, and its influence on clinical outcomes.

Leonie Fingerhut[1]; Ramakrishnan Vigneshwar[3]; Florence Burté[1]; Manojkumar Vimala Devi[2]; Rathinavel Sethu Nagarajan[2]; Rajarathinam Karpagam[2]; Venkatesh Prajna[3]; Bethany Mills[1]* and Prajna Lalitha[2]*

[1] Institute for Regeneration and Repair, The University of Edinburgh, UK

[2] Department of Ocular Microbiology, Aravind Eye Care System, Madurai, India

[3] Department of Cornea, Aravind Eye Care System, Madurai, India

*Correspondence to Dr Prajna Lalitha (lalitha@aravind.org) and Dr Bethany Mills (beth.mills@ed.ac.uk)

Synopsis (35 words):

We identified high incidence of multi-drug resistant fungi, and that patients were more likely to have a poor clinical outcome if the fungal isolate was resistant to natamycin. This was most pronounced for Aspergillus isolates.

Acknowledgements: BM, LF and FB were supported by a UKRI Future Leaders Fellowship (No. MR/V026097/1). For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission

Data availability statement: Data are available on reasonable request.

Ethics Statement: The study was approved by the Institutional Review Board of Aravind Eye Hospital, Madurai (RET202500520)

Abstract:

Aims: Primary objective: To determine the minimum inhibitory concentration (MIC) of key antifungal drugs (natamycin, amphotericin B, voriconazole and econazole) against fungal isolates cultured from fungal keratitis patients in South India. Secondary objective: to ascertain correlations between antifungal resistance and patient outcome.

Methods: In this prospective observational study, MIC values were determined for fungal isolates cultured from 153 patients, with samples collected between May – August 2025. Clinical characteristics were collected at baseline, one-week and one-month following enrolment to the study. Mean antifungal MIC per fungi genera were compared. Statistical differences in MIC and patient characteristics were determined via multiple logistic or linear regression. Significance for participant outcome against resistant/non-resistant fungi were determined by Fisher's exact test.

Results:

Resistance of *Fusarium* spp. isolates to: natamycin: 38.3%; amphotericin B: 93.8%; voriconazole: 97.5% and econazole: 76.5%. Resistance of *Aspergillus spp.* isolates to: natamycin: 66.7%; amphotericin B: 87.9%; voriconazole: 6.1%; and none were resistant to econazole. Natamycin MIC correlated with worse baseline ($P \leq 0.01$) and one-week ($P \leq 0.05$) visual acuity and ulcer severity. Poor patient outcomes (non-healing or therapeutic keratoplasty) were elevated 6.5x where the infection was caused by natamycin resistant *Aspergillus*, compared to sensitive *Aspergillus* strains ($P \leq 0.05$).

Conclusion: The majority of fungal isolates were resistant to multiple antifungals, none of the *Fusarium* isolates were sensitive to all four drugs, and 15% were resistant to all four drugs. *Aspergillu*s isolates had high levels of resistance to the polyenes, but remained largely susceptible to the azoles. Overall, worse patient outcomes were associated with increased natamycin MIC.

Key Messages (3-5 sentences each):

What is already known on this topic:

Fungal keratitis is a major cause of blindness worldwide, disproportionately affecting those across the tropics, with incidence increasing across temperate climates. The majority of cases are caused by the filamentous fungi *Fusarium* spp. and *Aspergillus* spp.. Antifungal resistance is poorly characterised in fungal keratitis.

What this study adds:

We report the fungal aetiology and the minimum inhibitory concentration (MIC) against natamycin, amphotericin B, voriconazole and econazole of isolates cultured from 153 patient corneal scrape samples between May – August 2025 at a South Indian hospital. We found high levels of fungal resistance, with *Fusarium* isolates having high levels of resistance to both polyenes and azoles. *Aspergillus* isolates showed good azole sensitivity, but high levels of resistance to polyenes. *Aspergillus* resistance to natamycin correlated with worse clinical outcomes at one-month. Natamycin resistance contributed to worse visual acuity and ulcer severity at baseline and one-week follow-up across all fungi.

How this study might affect research, practice or policy:

Our study confirmed that natamycin was best available first-line treatment for *Fusarium*. *Aspergillus* isolates were mostly resistant to natamycin and amphotericin B, and this impacted patient outcomes.

Introduction

Fungal keratitis remains a leading cause of visual impairment, blindness and eye-loss worldwide. It affects more than one million people annually, and corneal perforation is reported in up to 25% of cases (1, 2). While fungal keratitis disproportionality affects rural populations across the tropics, incidence is increasing across more temperate climates (3, 4).

Fungal keratitis is challenging to treat, resulting in worse outcomes compared to bacterial keratitis (5, 6). Treatment relies on topical application of antifungal eye-drops, and options are limited, primarily to two drug classes: polyenes (e.g., amphotericin B, natamycin); and azoles (e.g., voriconazole, econazole) (7, 8). Natamycin prevails as the first-line treatment option, with inclusion of voriconazole or other drugs if there is no positive response to treatment (8, 9). Better outcomes with natamycin compared to voriconazole topical treatment have been demonstrated, particularly for treating *Fusarium* spp. infections (10).

This paucity of antifungal drugs to treat fungal keratitis may be compounded (now or in the future) by the increasing global incidence of antifungal resistance (11, 12). While a broad spectrum of fungi (393 species) have been cultured from fungal keratitis patients (13), 95% of cases are caused by either *Aspergillus spp.*, *Fusarium spp.*, or *Candida spp*.. Each of these genera have been categorised by the world health organisation (WHO) as critical and high priority pathogens (14). Antimicrobial-resistant *Aspergillus* spp. is further included in the 2019 U.S. Centers for Disease Control and Prevention watch list, and drug-resistant *Candida* species are listed as serious threats (15).

Antifungal resistance testing of fungi cultured from fungal keratitis patients is often not routinely performed and/or reported, and therefore the scale of antifungal resistance is poorly understood. Herein we report on the antifungal resistance profile of fungal isolates obtained from 153 fungal keratitis patients from South India between May – August 2025. The minimum inhibitory concentration (MIC) against each of the key clinically used antifungals (natamycin, amphotericin B, voriconazole, and econazole) for treatment of fungal keratitis were determined. Participant clinical symptoms were evaluated at baseline upon enrolment in the study, after one week and after one month to explore the relationship between antifungal resistance and clinical features.

Materials and methods

This prospective observational study was performed in the Ocular Microbiology Laboratory of Aravind Eye Hospital, Madurai, India. The study was approved by the Institutional review board of Aravind Eye Hospital, Madurai (RET202500520).

The study included 153 consecutive culture-proven fungal keratitis cases from May to August 2025. After a detailed slit lamp biomicroscopic examination of each patient, visual acuity, location of the ulcer, size of the ulcer and clinical history were documented. These clinical details were documented at one-week and one-month follow-up appointments following the initial (baseline) visit, unless the patient did not attend the clinic and they were deemed "lost-to-follow up".

Corneal scraping specimens were collected at the first-appointment (at the time of study recruitment) under magnification by using a kimura spatula and evaluated with 10% potassium hydroxide wet mount and Gram stain. Subsequent scrapings were plated onto 5% sheep blood agar (incubated at 37°C) and potato dextrose agar (incubated at 25°C) and allowed to grow for at least seven days prior to testing. Any positive fungal isolate was identified to the genus or species level by Lactophenol cotton blue (LPCB) mount based on their spore morphology.

Antifungal susceptibility of filamentous fungi was determined using the broth microdilution method according to CLSI M38-A3 guidelines (16, 17). The following antifungal agents were tested with the final concentration: Natamycin (0.06-32 µg/mL), Voriconazole (0.03-16 µg/mL), Amphotericin B (0.03-16 µg/mL) and Econazole (0.03-16 µg/mL). The inoculum (conidial suspension) was prepared from 7-day-old cultures grown on potato dextrose agar and adjusted to a final inoculum of $0.4–5\times10^4$ CFU mL^{-1} in sterile saline with 0.05% Tween 20. Natamycin, Voriconazole, Amphotericin B, and Econazole were two-fold serially diluted in RPMI 1640 medium buffered with MOPS (pH 7.0). Each well of a 96-well microtiter plate was inoculated with 100 µL of fungal suspension and 100 µL of antifungal dilution, with growth and sterility controls included. The microtiter plates were incubated at 35°C for 48 to 72 hours. The minimum inhibitory concentration (MIC) was defined as the lowest concentration that exhibited a 100% visual reduction in turbidity when compared with the control tube for the polyenes (Natamycin and Amphotericin B) at 48 hours. An 80% reduction in turbidity was considered the end point for the azoles (Voriconazole and Econazole). Quality control was performed using reference strains.

MICs were interpreted according to CLSI breakpoints, epidemiological cut-off values where available. We used the following MIC breakpoints (18): Natamycin: ≥8.0 mg/L resistant; Amphotericin B: ≥2.0 mg/L resistant; Voriconazole: ≥2.0 mg/L resistant; and Econazole: ≥8.0 mg/L resistant. Susceptible-increased exposure fungal isolates were treated as susceptible for further evaluation.

Statistical analysis

Data were analysed using GraphPad Prism 9.5.1 (GraphPad Software, San Diego, CA, USA). For each antifungal tested, the mean antifungal MIC per fungi genera were compared using Kruskal-Wallis test followed by Dunn's multiple comparisons test.

Statistical differences were determined via multiple logistic or linear regression of log2-transformed MIC values and patient characteristics data. A mixed-effect analysis, followed by Tukey's multiple comparisons test was used to analyse the development of clinical symptoms over time. For these analyses, participants who were lost to follow-up were removed. Significance for participant outcome against resistant/non-resistant fungal strain was determined by Fisher's exact test on 3 x 2 contingency data, including lost to follow up patients.

Upset plots were produced using the UpSetR package in R (version R 4.5.0) (19).

Results

Participant demographics and sample aetiology

A total of 153 fungal keratitis patients with culture-positive samples were included in this study. Participants' ages ranged from seven to 88 years-old, with 59% identified as male (Table 1). Half of the recruited patients had already received ocular medication when first presenting at the Aravind Eye Hospital, and had symptoms for a median time of five days. Samples from 81 patients grew *Fusarium* species (52.9%), from 33 patients *Aspergillus* species (21.6%), and 25.5% were other filamentous fungi. These included *Bipolaris spp.*, *Chaetomiaceae spp.*, *Colletotrichum spp.*, *Curvularia spp.*, *Exserohilum spp.*, *Lasiodiplodia spp.*, *Mucor spp.*, *Paecilomyces spp.*, *Papulospora equi*, *Pleiocarpon algeriense*, *Podospora spp.*, and *Scedosporium spp* (Supplementary table 1).

Table 1. Baseline patient characteristics and final patient outcome

	N[a]		N[b]	(%)	Median	(IQR)
Sex	153	Male	90	(58.8)		
		Female	63	(41.2)		
Age	153	Years			51	(37-63)
Admission route	153	Free	89	(58.2)		
		Paying	64	(41.8)		
Durations of symptoms	149	Days			5	(3-7)
Prior ocular medication	153	Yes	77	(50.3)		
		No	76	(49.7)		
Visual acuity	153	LogMAR			1	(0.32-2.00)
Epithelial defect	149	mm^2			7.84	(1.5-16.0)

Table 1. Baseline patient characteristics and final patient outcome						
	N[a]		N[b]	(%)	Median	(IQR)
Stromal infiltrate depth	132	%			40	(30-70)
Ulcer severity score*	151	0-3			2	(2-2)
Fungal species cultured	153	*Fusarium* spp.	81	(52.9)		
		Aspergillus spp.	33	(21.6)		
		Other	39	(25.5)		
Final Outcome	153	Healed	59	(38.6)		
		Non-healed	32	(20.9)		
		Lost to follow-up	62	(40.5)		

N[a] = number of participants with data available. N[b] = number or participants per category. IQR = Interquartile range. *Severity score was recorded as: 0 = healed, 1 = mild, 2 = moderate, 3 = severe.

Antifungal minimum inhibitory concentrations (MICs) against cultured ocular clinical isolates

MICs were available for 151 fungal isolates against Natamycin, Amphotericin B, Voriconazole and Econazole. Across all isolates, the median MICs (interquartile range; IQR) were: 2.00 (1.00-8.00) µg/mL natamycin; 2.00 (0.50-8.00) µg/mL voriconazole; 2.00 (1.00-2.00) µg/mL amphotericin B; and 2.00 (0.50-8.00) µg/mL econazole. In total, 35.8% of the isolates were resistant to natamycin, 74.8% to amphotericin B, 58.3% to voriconazole and 41.7% to econazole.

Comparison of antifungal MICs for *Fusarium* and *Aspergillus* genera identified a different resistance pattern between them and the combined other genera (Figure 1, Supplementary figure 1).

The isolates of *Fusarium* spp., showed resistance against natamycin in 38.3% of cases, against amphotericin B in 93.8% of cases, against voriconazole in 97.5% of cases, and 76.5% of the isolates were resistant to econazole.

While the *Aspergillus spp.* isolates demonstrated high levels of resistance towards natamycin (66.7% of isolates) and amphotericin B (87.9% isolates), only 6.1 % of isolates were resistant to voriconazole, and none were resistant to econazole.

Fungal keratitis ocular isolate resistance to multiple antifungal drugs

Of the 151 fungal isolates with MIC data, just 27 isolates (17.9%) were sensitive to all four antifungal drugs tested, none of those isolates being *Fusarium* spp., and only one *Aspergillus flavus* isolate. The majority (66.9%) of the ocular isolates were resistant to more than one of the antifungals. Furthermore, 23 (15.2%) were resistant against all four antifungals, all of these isolates being *Fusarium* spp. (Figure 2).

Antifungal resistance: Clinical progression and participant outcomes

The study participants underwent clinical assessment at the time of enrolment (baseline, n=153); as well as after one week (n=120) and one month (n=83). Key clinical measures (visual acuity, epithelial defect area, stromal infiltrate depth, and ulcer severity score) are reported in supplementary table 2 and supplementary figure 2. Epithelial defects significantly improved across the cohort within one week (P<0.0001). There were marginal improvements in ulcer severity between baseline and one week (P=0.0256), which improved further by one month (P<0.0001). We found no significant associations between MIC values and sex, age, admission route, or whether ocular medication had been administered before samples were taken for fungal diagnostics.

Natamycin: There was a significant correlation between natamycin MIC and a number of clinical measures. Increased natamycin MIC correlated with worse baseline visual acuity (P=0.0028) and at the one-week follow-up (P=0.0332). Similar trends were observed for the size of the epithelial defect at the baseline (P=0.0323) and one-week follow-up (P=0.0187); the stromal infiltrate depth at baseline (p=0.0055); and for the ulcer severity score at baseline (P=0.0016) and one-week follow-up (P=0.0079). We also determined that symptom duration prior to study enrolment correlated positively with natamycin MIC (P=0.0007).

Fungal resistance towards natamycin also significantly affected the patient outcome, 35.2% of patients had a poor-outcome (not-healed) if their infection was natamycin resistant, compared to just 13.4% of natamycin sensitive infections (P=0.0078, table 2), with MIC correlating significantly with outcome (P=0.0006). Species sub-analysis determined that this relationship was genera dependent, and was significant for cases caused by *Aspergillus* spp. (P=0.0153), but not for keratitis caused by *Fusarium* spp.

Amphotericin B: We found fewer significant correlations between amphotericin B MIC and clinical outcomes. However, higher MICs were related to increased stromal infiltrate depth at baseline (P=0.039) and a higher one-week ulcer severity score (P=0.0264). Fungal resistance towards amphotericin B did not correlate with patient outcomes (table 2).

Voriconazole and Econazole: While we did not find any association between voriconazole and econazole MICs against participant ulcer characteristics and clinical outcomes, there was a significant correlation between econazole and voriconazole MICs (P<0.0001), and between voriconazole and amphotericin B MICs (P=0.033).

Table 2. Fungal resistance in relation to patient outcome								
		Patient Outcome						
		Healed		Non-healed		Lost to follow-up		P
	N[a]	N[b]	(%)	N[b]	(%)	N[b]	(%)	
All Fungal Isolates								
Natamycin	151							**0.0078**
Non-resistant	*97*	43	(44.3)	13	(13.4)	41	(42.3)	
Resistant	*54*	16	(29.6)	19	(35.2)	19	(35.2)	
Amphotericin B	151							NS
Non-resistant	*38*	15	(39.5)	6	(15.8)	17	(44.7)	
Resistant	*113*	44	(38.9)	26	(23.0)	43	(38.1)	
Voriconazole	150							NS
Non-resistant	*63*	21	(33.3)	16	(25.4)	26	(41.3)	
Resistant	*87*	38	(43.7)	15	(17.2)	34	(39.1)	
Econazole	146							NS
Non-resistant	*87*	32	(36.8)	21	(24.1)	34	(39.1)	
Resistant	*59*	26	(44.1)	9	(15.3)	24	(40.7)	
***Fusarium* spp. Isolates**								
Natamycin	81							NS
Non-resistant	*50*	25	(50.0)	6	(12.0)	19	(38.0)	
Resistant	*31*	12	(38.7)	6	(19.4)	13	(41.9)	
Amphotericin B	81							NS
Non-resistant	*5*	1	(20.0)	0	(0.0)	4	(80.0)	
Resistant	*76*	36	(47.4)	12	(15.8)	28	(36.8)	
Voriconazole	81							NS
Non-resistant	*2*	1	(50.0)	0	(0.0)	1	(50.0)	
Resistant	*79*	36	(45.6)	12	(15.2)	31	(39.2)	
Econazole	77							NS
Non-resistant	*20*	10	(50.0)	2	(10.0)	8	(40.0)	
Resistant	*57*	26	(45.6)	8	(14.0)	23	(40.4)	
***Aspergillus* spp. Isolates**								
Natamycin	33							**0.0153**
Non-resistant	*11*	4	(36.4)	1	(9.1)	6	(54.5)	
Resistant	*22*	3	(13.6)	13	(59.1)	6	(27.3)	
Amphotericin B	33							NS
Non-resistant	*4*	1	(25.0)	2	(50.0)	1	(25.0)	
Resistant	*29*	6	(20.7)	12	(41.4)	11	(37.9)	
Voriconazole	33							NS
Non-resistant	*31*	7	(22.6)	13	(41.9)	11	(35.5)	
Resistant	*2*	0	(0.0)	1	(50.0)	1	(50.0)	
Econazole	33							NS
Non-resistant	*33*	7	(21.2)	14	(42.4)	12	(36.4)	
Resistant	*0*	0		0		0		

Table 2. Fungal resistance in relation to patient outcome								
		Patient Outcome						
		Healed		Non-healed		Lost to follow-up		P
	N[a]	N[b]	(%)	N[b]	(%)	N[b]	(%)	
N[a] = Number of participants with data available N[b]= Number of participants with a specific outcome. Statistical analysis determined by Fisher's exact test on contingency data comparing patient outcomes for resistant vs non-resistant fungi. NS = not significant.								

Discussion

Antifungal resistance is of increasing concern due to the paucity of antifungal treatments available. Increasing trends have been reported worldwide, often attributed to increased use of fungicides (azoles) in agriculture and industry, and improper medical application (20). The majority of fungi in our study were resistant to two or more antifungals, including those from both polyene and azole classes. Few studies have reported the antifungal resistance profile of isolates cultured from fungal keratitis patients, and where resistance is reported, differences in resistance breakpoints among studies make comparisons challenging (9, 21-23).

However, a large study from the UK (using the same resistance break-points as used within our study) recently examined the antifungal MICs of corneal and contact lens isolates (18). While our study found a similar proportion of fungal isolates resistant to econazole (~40%), a substantially higher proportion of our isolates showed resistance to natamycin (36% vs 8.2%), amphotericin B (74.8% vs 27.2%) and voriconazole (58.3% vs 27%). This was more pronounced when comparing data from *Fusarium* spp., and *Aspergillus* spp. isolates across each of the antimicrobials. For example, none of the UK *Fusarium* spp. isolates showed resistance to natamycin, compared to almost 40% of our isolates. Our study identified that 94% of *Fusarium* spp. isolates were resistant to amphotericin B, compared to just one-third in the UK study, and 88% of the *Aspergillus* spp. isolates in our study were resistant to amphotericin B compared to just 3% in the UK study. These differences echo geographical differences also observed for antimicrobial resistance against bacterial isolates and highlight the need for region-specific antimicrobial resistance surveillance.

Antimicrobial resistance patterns can shift quickly, and understanding antifungal resistance in a local and temporal context is imperative for implementing appropriate treatment guidelines. When applying our resistance thresholds to antifungal MIC data collected from our Centre between 2010-2018 (9), we found that the proportion of *Aspergillus* spp. isolates resistant to natamycin has decreased, from 90% of the isolates being resistant in the previous study, compared to 67% of isolates in this study. There was no change in the rate of voriconazole resistance for either fungal genus, and azoles remain relatively effective against *Aspergillus* spp. *in vitro.*

Our study also sought to correlate antifungal MICs with clinical outcomes. We determined that higher natamycin MICs did correlate with a number of clinical measures, including worse visual acuity, and ulcer severity score at baseline and one-week follow-up. We also found that increased natamycin MIC correlated with longer symptom duration prior to attending our cornea clinic. While we did not specifically examine MIC in relation to treatment before attending our clinic, we know that patients with longer symptom duration are likely to have been treated elsewhere; and 50% of our participants had received treatment prior to enrolling. Antimicrobial MICs have previously been shown to be higher for specimens collected after treatment initiation for both fungi and bacteria, compared to those sampled from treatment-naive patients (24, 25). This is an area that warrants further study.

Importantly, our study identified that patients were 2.5 times more likely to have a poor clinical outcome (not healed at one month, or requiring therapeutic keratoplasty) if the fungal isolate was resistant to natamycin; and that this was more pronounced for natamycin resistant *Aspergillus* spp. isolates, where poor outcomes were increased 6.5 times compared to patients with sensitive *Aspergillus* strains. We did not find this correlation for any of the other antifungal drugs. These findings corroborate those reported from our MUTT-I study (samples collected 2010-2011) (26). However, they are in contrast with those reported from our MUTT-II study (samples collected 2010-2015) (27), where no correlation between clinical outcomes and natamycin resistance were identified. This further highlights the need for standardised methodology and continued antimicrobial resistance surveillance.

As already discussed, few fungal keratitis antifungal resistance studies have been reported, and even fewer have reported concurrent multidrug resistance profiles and/or patient outcomes. This is a particular strength of our study. A limitation of ours and other studies is the lack of standardised, clinically appropriate MIC breakpoints for fungal keratitis. MICs are typically based on systemic drug concentrations, rather than topical application, where the local concentration of the drug may be higher. They also do not consider the increased MIC required to treat fungal biofilms, which can be prevalent in fungal keratitis cases (4, 28). A systematic review on the topic is warranted to consolidate the literature and identify key areas of uncertainty (29) and contribute to standardised reporting methodology, MIC breakpoints and treatment guidelines for fungal keratitis.

References

1. Hoffman JJ, Burton MJ, Leck A. Mycotic Keratitis-A Global Threat from the Filamentous Fungi. J Fungi (Basel). 2021;7(4):273. DOI: 10.3390/jof7040273
2. Brown L, Leck AK, Gichangi M, Burton MJ, Denning DW. The global incidence and diagnosis of fungal keratitis. The Lancet Infectious Diseases. 2021;21(3):e49-e57. DOI: 10.1016/S1473-3099(20)30448-5
3. Ong HS, Fung SSM, Macleod D, Dart JKG, Tuft SJ, Burton MJ. Altered Patterns of Fungal Keratitis at a London Ophthalmic Referral Hospital: An Eight-Year Retrospective Observational Study. Am J Ophthalmol. 2016;168:227-36. DOI: 10.1016/j.ajo.2016.05.021
4. Fingerhut L, Cheng KKW, Ali A, Mills B. Implications of Fungal Biofilms in Microbial Keratitis. Fungal Biofilms. 2025:335-94. DOI: https://doi.org/10.1007/978-3-031-93315-8_15
5. Mills B, Radhakrishnan N, Karthikeyan Rajapandian SG, Rameshkumar G, Lalitha P, Prajna NV. The role of fungi in fungal keratitis. Exp Eye Res. 2021;202:108372. DOI: 10.1016/j.exer.2020.108372
6. Prajna NV, Srinivasan M, Lalitha P, Krishnan T, Rajaraman R, Ravindran M, et al. Differences in clinical outcomes in keratitis due to fungus and bacteria. JAMA Ophthalmol. 2013;131(8):1088-9. DOI: 10.1001/jamaophthalmol.2013.1612
7. Hoffman JJ, Arunga S, Mohamed Ahmed AH, Hu VH, Burton MJ. Management of filamentous fungal keratitis: a pragmatic approach. Journal of Fungi. 2022;8(10):1067. DOI: 10.3390/jof8101067
8. Awad R, Ghaith AA, Awad K, Mamdouh Saad M, Elmassry AA. Fungal Keratitis: Diagnosis, Management, and Recent Advances. Clin Ophthalmol. 2024;18:85-106. DOI: 10.2147/OPTH.S447138
9. Prajna NV, Lalitha P, Krishnan T, Rajaraman R, Radnakrishnan N, Srinivasan M, et al. Patterns of Antifungal Resistance in Adult Patients With Fungal Keratitis in South India: A Post Hoc Analysis of 3 Randomized Clinical Trials. JAMA Ophthalmology. 2022;140(2):179-84. DOI: 10.1001/jamaophthalmol.2021.5765
10. Prajna NV, Krishnan T, Mascarenhas J, Rajaraman R, Prajna L, Srinivasan M, et al. The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole. JAMA Ophthalmol. 2013;131(4):422-9. DOI: 10.1001/jamaophthalmol.2013.1497
11. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383-e92. DOI: 10.1016/S1473-3099(17)30316-X
12. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739-42. DOI: 10.1126/science.aap7999
13. Bartimote C, Foster J, Watson S. The spectrum of microbial keratitis: An updated review. The Open Ophthalmology Journal. 2019;13(1):100-30. DOI: 10.2174/1874364101913010100
14. WHO fungal priority pathogens list to guide research, development and public health action. Geneva: World Health Organization; 2022.
15. U.S. Department of Health and Human Services C. Antibiotic Resistance Threats in the United States. 2019.
16. CLSI document M38-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
17. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard—Third Edition.: Clinical and Laboratory Standards Institute.
18. Tuft S, Stone NRH, Burton MJ, Johnson EM, Borman AM. Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom. Eye (Lond). 2024;38(3):529-36. DOI: 10.1038/s41433-023-02719-1
19. Conway JR, Lex A, Gehlenborg N. UpSetR: an R package for the visualization of intersecting sets and their properties. Bioinformatics. 2017;33(18):2938-40.
20. Verweij PE, Lucas JA, Arendrup MC, Bowyer P, Brinkmann AJF, Denning DW, et al. The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biol Rev. 2020;34(4):202-14. DOI: 10.1016/j.fbr.2020.10.003

21. Soleimani M, Izadi A, Khodavaisy S, Dos Santos CO, Tehupeiory-Kooreman MC, Ghazvini RD, et al. Fungal keratitis in Iran: Risk factors, clinical features, and mycological profile. Front Cell Infect Microbiol. 2023;13:1094182. DOI: 10.3389/fcimb.2023.1094182
22. Xie L, Zhai H, Zhao J, Sun S, Shi W, Dong X. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China. Am J Ophthalmol. 2008;146(2):260-5. DOI: 10.1016/j.ajo.2008.04.019
23. Manikandan P, Abdel-Hadi A, Randhir Babu Singh Y, Revathi R, Anita R, Banawas S, et al. Fungal Keratitis: Epidemiology, Rapid Detection, and Antifungal Susceptibilities of Fusarium and Aspergillus Isolates from Corneal Scrapings. Biomed Res Int. 2019;2019:6395840. DOI: 10.1155/2019/6395840
24. Sun CQ, Prajna NV, Krishnan T, Rajaraman R, Srinivasan M, Raghavan A, et al. Effect of pretreatment with antifungal agents on clinical outcomes in fungal keratitis. Clin Exp Ophthalmol. 2016;44(9):763-7. DOI: 10.1111/ceo.12794
25. Ray KJ, Prajna L, Srinivasan M, Geetha M, Karpagam R, Glidden D, et al. Fluoroquinolone treatment and susceptibility of isolates from bacterial keratitis. JAMA ophthalmology. 2013;131(3):310-3. DOI: 10.1001/jamaophthalmol.2013.1718
26. Sun CQ, Lalitha P, Prajna NV, Karpagam R, Geetha M, O'Brien KS, et al. Association between in vitro susceptibility to natamycin and voriconazole and clinical outcomes in fungal keratitis. Ophthalmology. 2014;121(8):1495-500 e1. DOI: 10.1016/j.ophtha.2014.03.004
27. Lu L, Prajna NV, Lalitha P, Rajaraman R, Srinivasan M, Arnold BF, et al. Association between in vitro susceptibility and clinical outcomes in fungal keratitis. J Ophthalmic Inflamm Infect. 2024;14(1):42. DOI: 10.1186/s12348-024-00418-w
28. Zhang X, Sun X, Wang Z, Zhang Y, Hou W. Keratitis-associated fungi form biofilms with reduced antifungal drug susceptibility. Invest Ophthalmol Vis Sci. 2012;53(12):7774-8. DOI: 10.1167/iovs.12-10810
29. Tuft S, Evans J, Gordon I, Leck A, Stone N, Neal T, et al. Antimicrobial resistance in topical treatments for microbial keratitis: protocol for a systematic review and meta-analysis. BMJ Open. 2023;13(3):e069338. DOI: 10.1136/bmjopen-2022-069338



Figure 1. Minimum inhibitory concentrations (MICs) of antifungals against fungal keratitis isolates. MIC [µg/mL] of the antifungals **a)** natamycin, **b)** amphotericin B, **c)** voriconazole and **d)** econazole against fungal isolates cultured from fungal keratitis patients. Cut-off values for resistance are 8 µg/mL for natamycin and econazole, and 2 µg/mL for voriconazole and amphotericin B (depicted by horizontal line). Statistical analysis was performed by Kruskal-Wallis test followed by Dunn's multiple comparisons test (**p<0.01, ***p<0.001, ****p<0.0001). Each data point represents one isolate.



Figure 2. Concurrent resistance of fungal keratitis isolates to antifungal drugs. Upset plots depicting the number of **a)** all fungal isolates; **b)** *Fusarium* spp., and **c)** *Aspergillus* spp. isolates with resistance to common antifungal drugs. MIC cut-off values for resistance are 8 µg/mL for natamycin and econazole, and 2 µg/mL for voriconazole and amphotericin B. Black dots indicate resistance.